The study will include around 200 participants aged 65 or older with BMI of at least 35 starting semaglutide therapy.

A recent research study found that a combination of the GLP-1 receptor agonist semaglutide and bimagrumab, an antibody that ...

Dual therapy with a GLP-1 receptor agonist plus ixekizumab demonstrates long-term benefits in psoriatic disease activity, ...

Preliminary safety data from a French registry on combination therapy in immune-mediated inflammatory diseases (IMIDs) show a concerning rate of serious infections and illustrate the need for ...

Acute myeloid leukemia (AML) is a particularly aggressive form of blood cancer that usually progresses rapidly if swift and intensive treatment is not applied. Although the disease can often be ...

Epcoritamab plus R-DHAX/C achieved 79% ORR and 69% CR, with median 1.4 months to response and early activity evident by the first week-6 assessment. Over half of patients reached ASCT after ...

Please provide your email address to receive an email when new articles are posted on . Adults with type 2 diabetes and CKD had a greater UACR reduction with finerenone plus empagliflozin vs. either ...

Initiated higher-dose CBeyond Expansion Study (Part C) to generate higher-exposure human safety and pharmacokinetic data with 400 mg and 600 mg ...

Add Yahoo as a preferred source to see more of our stories on Google. For men facing the return of prostate cancer, a new combination therapy may offer a much longer break before the disease comes ...

A combination of brexpiprazole (Rexulti) and sertraline improved post-traumatic stress disorder (PTSD) symptoms more than sertraline alone, a phase III trial found. The primary endpoint was the change ...